IADR Abstract Archives
Salivary sPD-1 as potential diagnostic tool in PCN patients
Objectives: Pancreatic cancer (PC) is associated with poor prognosis partially due to a severe lack of diagnostic tools for early detection. Recent studies suggest a link between oral health and PC, suggesting potential salivary biomarkers as diagnostic tools. We characterized soluble immune checkpoint (sIC) profile in salivary, plasma and pancreatic cyst fluid (CF) samples from patients diagnosed with pancreatic cystic neoplasm (PCN) who were undergoing pancreatic resection surgery. The objective was to determine the suitability of saliva as the diagnostic fluid to determine sIC levels, the correlation between salivary and CF levels of sICs, and the association between salivary sIC levels and pancreatic dysplastic progression.
Methods: Saliva, blood plasma and pancreatic CF were obtained from 47 PCN patients undergoing pancreatic resection surgery. A panel of ten select sICs was quantified in saliva, plasma and CF using Luminex technology. We then determined the correlation between salivary levels of the sICs and their levels in the CF compartment, as well as the association between salivary sIC levels and post-operative histopathological classification according to dysplastic progression.
Results: All sICs included were detectable by Luminex in all three compartments studied. sPD-1 level in saliva and CF showed a strong correlation (R2=0.647, p<.001). However, a significant association between salivary sPD-1 level and pancreatic dysplastic progression could not be established. Some of the sICs measured showed possible trends associated with dysplastic progression in saliva (sCD40), plasma (sGITR) or CF (sBTLA, sCD40), however none of these reached significance.
Conclusions: Luminex technology can be used to detect the levels of sICs in patient saliva, underscoring saliva's importance as an easily and non-invasively collected diagnostic fluid. Furthermore, sPD-1 level in patient saliva correlates with sPD-1 level in the CF from patients diagnosed with pancreatic cystic neoplasms. While we were not able to establish a definite relationship between salivary sPD-1 and dysplastic progression in the pancreas, this finding demonstrates the potential of using salivary sPD-1 as an accessory biomarker in diagnosing types of cancer associated with PD-1 dysregulation.
Methods: Saliva, blood plasma and pancreatic CF were obtained from 47 PCN patients undergoing pancreatic resection surgery. A panel of ten select sICs was quantified in saliva, plasma and CF using Luminex technology. We then determined the correlation between salivary levels of the sICs and their levels in the CF compartment, as well as the association between salivary sIC levels and post-operative histopathological classification according to dysplastic progression.
Results: All sICs included were detectable by Luminex in all three compartments studied. sPD-1 level in saliva and CF showed a strong correlation (R2=0.647, p<.001). However, a significant association between salivary sPD-1 level and pancreatic dysplastic progression could not be established. Some of the sICs measured showed possible trends associated with dysplastic progression in saliva (sCD40), plasma (sGITR) or CF (sBTLA, sCD40), however none of these reached significance.
Conclusions: Luminex technology can be used to detect the levels of sICs in patient saliva, underscoring saliva's importance as an easily and non-invasively collected diagnostic fluid. Furthermore, sPD-1 level in patient saliva correlates with sPD-1 level in the CF from patients diagnosed with pancreatic cystic neoplasms. While we were not able to establish a definite relationship between salivary sPD-1 and dysplastic progression in the pancreas, this finding demonstrates the potential of using salivary sPD-1 as an accessory biomarker in diagnosing types of cancer associated with PD-1 dysregulation.